Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Organon & Co. Director's Dealing 2021

Jun 8, 2021

31461_dirs_2021-06-08_4268c767-6634-4ad3-b95c-d786d7cf60d3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Organon & Co. (OGN)
CIK: 0001821825
Period of Report: 2021-06-04

Reporting Person: Patton Cynthia M (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-04 Phantom Stock $ A 8772 Acquired Common Stock (8772) Direct

Footnotes

F1: 1-for-1

F2: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.